Closing Stock Market SummaryThe S&P 500 (+0.8%) and Dow Jones Industrial Average (+0.9%) set intraday and closing record highs on Friday, with the benchmark index topping the 4100 level for the first time. The Nasdaq Composite (+0.5%) overcome an early decline to close positive. The Russell 2000 (+0.04%) sneaked into the green amid a strong finish in the broader market.
The session started with the market brushing off a hotter-than-expected Producer Price Index report for March, which showed producer prices for final demand increase 1.0% m/m (Briefing.com consensus +0.5%) and 4.2% yr/yr. Despite the potential for a spillover into consumer prices, the market trusted the Fed's thinking it'll be transitory.
The difference makers today came out of the heavily-weighted S&P 500 information technology (+1.0%) and consumer discretionary (+1.2%) sectors, which boasted strong performances from Apple (AAPL 133.00, +2.64, +2.0%) and Amazon (AMZN 3372.20, +72.90, +2.2%) in a continuation of their monthly outperformances.
Buying activity increased noticeably into the close on no confirmed catalyst, with the health care (+1.2%), industrials (+1.0%), and financials (+0.9%) sectors rounding out the top spots. Conversely, the energy (-0.5%), consumer staples (-0.1%), and utilities (-0.1%) sectors closed slightly lower.
The health care sector advanced without the leadership of Johnson & Johnson (JNJ 161.25, -1.72, -1.0%), which lost ground amid concerns surrounding the rollout and safety of its COVID-19 vaccine. Within the industrials sector, Boeing (BA 252.36, -2.59, -1.0%) advised customers to address a potential electrical issue in a specific group of 737 MAX planes prior to further operations.
Separately, the latest Flow Show report from BofA Securities indicated that total global equity inflows over the past five months ($576 billion) has exceeded total inflows for the past 12 years ($425 billion). Some attributed this eye-popping statistic to the muted price action during most of the day, but there still appeared to be an underlying hunger for risk assets.
In the Treasury market, the 10-yr yield settled three basis points higher at 1.67%, or slightly lower than where it was trading immediately before, and after, the PPI data. The 2-yr yield increased one basis point to 0.15%. The U.S. Dollar Index increased 0.1% to 92.17. WTI crude futures decreased 0.5%, or $0.32, to $59.29/bbl.
Reviewing Friday's economic data:
- The Producer Price Index for final demand increased 1.0% month-over-month in March consensus +0.5%). The index for final demand, excluding food and energy, jumped 0.7% m/m (Briefing.com consensus +0.2%. On a year-over-year basis, the index for final demand was up 4.2% (highest since 12 months ending September 2011), versus 2.8% in February. The index for final demand, excluding food and energy, was up 3.1% yr/yr, versus 2.5% in February.
- The key takeaway from the report isn't in the headline numbers. They are important, but the key takeaway is the pipeline pressures evident in the index for processed goods for intermediate demand, which increased 4.0% m/m in March (largest jump since August 1974), and in the index for unprocessed goods for intermediate demand, which surged 9.3% m/m (highest since November 2006). Those large increases point to inflation issues that are apt to linger for producers and which could potentially spill over into consumer prices.
- Wholesale inventories increased 0.6% m/m in February (consensus 0.5%) following an upwardly revised 1.4% increase (from +1.3%) in January.
Looking ahead, investors will receive the March Treasury Budget on Monday.
- Russell 2000 +13.6% YTD
- Dow Jones Industrial Average +10.4% YTD
- S&P 500 +9.9% YTD
- Nasdaq Composite +7.9% YTD
Gapping down
In reaction to earnings/guidance:
- JKS -10.9%, WDFC -7.3%, PSMT -3%, IMOS -0.6% (Q1 revs), TSM -0.5% (March Sales)
Other news:
- PRVB -37.9% (FDA identifies deficiencies in BLA application for teplizumab)
- ITRM -15.5% (discloses FDA notice that it needs more time to review materials that have been provided by the company)
- GSL -5.4% (stock offering)
- DLPN -4.7% (says some prior financials should no longer be relied upon due to accounting error)
- SNDX -4.6% (FDA grants Orphan Drug Designation to axatilimab)
- RMBL -4.4% (prices offering of 1,048,998 shares of its Class B Common Stock at $38.00 per share)
- KMPH -2.4% (amends licensing agreement with Gurnet Point Capital following FDA approval of AZSTARYS)
- UCTT -1.5% (prices offering of 3,181,818 shares of its common stock at $55.00 per share)
- ORTX -1% (ADS offering)
Analyst comments:
- CS -2.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- BTI -2.4% (downgraded to Neutral from Overweight at JP Morgan)
- ATUS -1.6% (downgraded to Neutral from Buy at Citigroup)
- BCC -1.2% (downgraded to Neutral from Buy at DA Davidson)
- CHUY -1.1% (downgraded to Hold from Buy at Stifel)
- GD -0.8% (downgraded to Underperform from Outperform at Wolfe Research)
Gapping up
In reaction to earnings/guidance:
- LEVI +5.5% (also increases dividend), AFYA +2.2% (also announces acquisition of Medical Harbour), SMG +1.4% (raises FY21 rev guidance above consensus; raises EPS guidance above consensus at the mid-point)
Other news:
- CELC +52.7% (PFE announces licensing agreement with CELC for gedatolisib)
- GLSI +29% (reports Phase IIb data supporting GP2 clinical outcome of 0% metastatic breast cancer recurrences over 5 years)
- AFMD +27.5% (presents Phase 1 study of cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13 at AACR)
- LHDX +14.6% (confirmed it can successfully identify the "double mutant" variant of COVID-19 with its Lucira molecular test kit)
- TXMD +9.1% (announces approvals for BIJUVE in the UK and Belgium)
- FUBO +8.4% (acquires streaming rights to the Qatar World Cup 2022)
- SOGO +6% (reports circulate that China's antitrust regulators are poised to clear Tencent's (TCEHY) buyout of SOGO)
- TRQ +4.2% (Turquiose Hill Resources and Rio Tinto (RIO) signs agreement for funding Oyu Tolgoi)
- RDHL +4% (reports Phase 2/3 COVID-19 study of Opaganib passes fourth DSMB review)
- SUNW +3.4% (to acquire Solcius)
- HGEN +3.1% (announces positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme)
- IOVA +2.8% (announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma)
- GSX +2.8% (firmly denies the false and ungrounded allegations raised in a report by Grizzly Research; believes report contains numerous errors, unsubstantiated statements, and misinterpretation of information)
- UPST +2.6% (prices follow-on offering of 2 mln shares of common stock at $120.00 per share)
- NBIX +2.5% (to present data from its Neurology portfolio)
- BKD +2% (reports March occupancy metrics)
- CCK +2% (to sell its European Tinplate business to KPS Capital for €1.9 bln; also to sell its EMEA food and consumer packaging business to KPS Capital for €2.25 bln)
- JCI +1.5% (acquires Silent-Aire; to be immediately accretive to FY22 earnings)
Analyst comments:
- DAN +2.7% (upgraded to Overweight from Equal Weight at Barclays)
- CCL +2.1% (upgraded to Outperform from Neutral at Credit Suisse)
- COMM +2.1% (upgraded to Buy from Neutral at Rosenblatt)
- OKTA +2.1% (upgraded to Buy from Neutral at BTIG Research)
- HON +2% (upgraded to Buy from Hold at Deutsche Bank)
- PM +1.3% (upgraded to Overweight from Neutral at JP Morgan)
- IBA +1.1% (upgraded to Overweight from Neutral at JP Morgan)